

AD _____

GRANT NUMBER DAMD17-97-1-7249

TITLE: Effects of FOS, JUN, TGF-B, and Glucorticoids on
Polarized Membrane Traffic

PRINCIPAL INVESTIGATOR: Keith E. Mostov, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of California, San Francisco
San Francisco, California 94143-0962

REPORT DATE: October 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1998	3. REPORT TYPE AND DATES COVERED Annual (30 Sep 97 - 29 Sep 98)	
4. TITLE AND SUBTITLE Effects of FOS, JUN, TGF-B, and Glucorticoids on Polarized Membrane Traffic			5. FUNDING NUMBERS DAMD17-97-1-7249	
6. AUTHOR(S) Mostov, Keith E., M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, San Francisco San Francisco, California 94143-0962			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			19990319 016	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) <p>Mammary cells undergo a physiological cycle of growth, differentiation, lactation, and involution. During transformation mammary cells lose polarity, and the extent of loss of polarity correlates with the degree of malignancy. The physiological and oncogenic changes in mammary cell polarity can be studied using highly differentiated cultured mammary epithelial cell lines, such as the 31EG4 cell clone. Glucocorticoids cause an increase in polarity. In contrast, exposure to TGFβ or over-expression of oncogenes (c-Fos or c-Jun) cause a spectrum of loss of polarity. For instance, c-Jun over-expression causes a reversible, partial loss of polarity, whereas over-expression of c-Fos causes a severe and irreversible loss of polarity. In contrast, exposure to TGFβ acts primarily to antagonize glucocorticoids, and physiologically is probably involved in involution of the mammary gland.</p> <p>In this grant proposal we have been studying the normal pathways used for polarized membrane traffic in well-differentiated cultured mammary epithelial cells. We have begun to study the effects of glucocorticoids, addition of TGFβ, or overexpression of c-Jun or c-Fos on these pathways.</p>				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 15	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

KEM Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

_____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

KEM In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

KEM In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

_____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

8/11/98
Date

TABLE OF CONTENTS

	PAGE
FRONT COVER.....	1
SF 298, REPORT DOCUMENTATION PAGE.....	2
FOREWORD.....	3
TABLE OF CONTENTS.....	4
INTRODUCTION.....	5-6
BODY.....	7-12
CONCLUSIONS.....	13
REFERENCES.....	14
APPENDICES.....	15

Introduction

Greater than 80% of breast cancers are derived from epithelial cells. Epithelial cells are highly polarized, with separate apical and basolateral surfaces facing the lumen and adjacent cells, respectively. The apical and basolateral surfaces contain very distinct protein compositions, which are essential to the proper functioning of the cell. The establishment and maintenance of cell polarity requires that proteins be sent to the correct surface. Epithelial cells use two pathways to send proteins to the correct surface: direct delivery from the TGN to the surface or transcytosis. A great deal has been learned about polarized membrane trafficking in certain model epithelial cells, such as Madin-Darby canine kidney cells. In contrast, although the polarized steady state distribution of several proteins has been determined in normal and transformed mammary cells, very little is known about the pathways and mechanisms used for polarized trafficking in mammary cells.

Mammary cells undergo a physiological cycle of growth, differentiation, lactation, and involution. During transformation mammary cells lose polarity, and the extent of loss of polarity correlates with the degree of malignancy. The physiological and oncogenic changes in mammary cell polarity can be studied using highly differentiated cultured mammary epithelial cell lines, such as the 31EG4 cell clone. Glucocorticoids cause an increase in polarity. In contrast, exposure to TGF β or over-expression of oncogenes (c-Fos or c-Jun) cause a spectrum of loss of polarity. For instance, c-Jun over-expression causes a reversible, partial loss of polarity, whereas over-expression of c-Fos causes a severe and irreversible loss of polarity. In contrast, exposure to TGF β acts primarily to antagonize glucocorticoids, and physiologically is probably involved in involution of the mammary gland.

In this grants have been studying the normal pathways used for polarized membrane traffic in well-differentiated cultured mammary epithelial cells. We will then move on to the effects of glucocorticoids, addition of TGF β , or overexpression of c-Jun or c-Fos on these pathways. We will examine the effects of these manipulations on expression and localization of syntaxins, which are a family of proteins that appear to control the specific targeting of vesicles to either the apical or basolateral surfaces of the cell. Finally, we will determine if overexpression of different syntaxins can correct the defects in membrane traffic caused by the manipulations that disrupt cell polarity. We have also been examining the roles of Pak1 and raf on cell polarity and membrane traffic.

The majority of breast cancers are epithelial in origin. 75% are derived from the ductal epithelium, while 5-10% are derived from lobular epithelial cells (1, 2, 3). Simple epithelia form a layer which acts as a highly selective barrier between the lumen of the duct or lobule and the adjoining and underlying cells. To achieve this the structure of epithelial cells is highly polarized. This is manifested in the maintenance of two distinct plasma membrane (PM) domains: an apical domain comprising the luminal surface, and a basolateral domain contacting adjoining and underlying cells. These two PM domains have very different protein compositions. Generation and maintenance of cell polarity is essential to epithelial function. This requires sorting PM proteins to the correct apical or basolateral surface. The polarity of mammary cells changes as they undergo the physiological cycle of growth, differentiation, and involution. An early hallmark of epithelial transformation is the loss of functional and morphological polarity.

In recent years we have learned a great deal about how PM proteins are sent to the apical or basolateral domain. Almost all of this work has been in non-mammary epithelial cells, especially the Madin-Darby canine kidney (MDCK) cell line (4, 5, 6). Much less is known about how the pathways and mechanisms of polarized traffic are altered as cells undergo physiologic differentiation and de-differentiation or as the cells undergo transformation. The fundamental innovation of this proposal is to apply our advances in studying polarized membrane traffic to the alterations in mammary cell polarity caused by a variety of physiological (e.g. exposure to glucocorticoids or TGF β) or oncogenic factors (over-expression of c-Jun or c-Fos oncogenes).

Alterations in polarized membrane traffic are highly relevant to breast cancer for several reasons. The delivery of growth factors and their receptors to the cell surface must be controlled. Mammary epithelial cells are responsive to many growth factor receptors at their basolateral PM, such as EGF, TGF- α , TGF- β and PDGF. They can also secrete these factors from their apical cell surface. Correct

targeting of these growth factors is essential to control their growth (7, 8, 9). On another level polarized trafficking is important because many growth factors are first formed as larger proteins, and their proteolytic products are considered the active form. However, if not processed properly, the membrane bound protein is still active. Clearly, proper expression and localization of the processing enzymes is critical.

In general in epithelial tumors the degree of malignancy is correlated with extent of loss of polarity. Cultured mammary cells can be transformed to varying degrees by regulated expression of various oncogenes. For instance, c-Jun over-expression gives a reversible transformation and loss of polarity, while sustained c-Fos overexpression gives an irreversible, more severe transformation and loss of cell polarity.

Understanding how polarized membrane changes during physiological and oncogenic processes has several clinical implications. Like colon and other cancers, it is likely that breast cancers undergo a progression of increasing malignancy. With modern diagnostic techniques many very early breast cancers (e.g. ductal carcinoma in situ) are now being detected. It is difficult, yet vitally important, to predict which of these will progress to more serious malignancies. In this grant proposal we will examine how a spectrum of physiological and oncogenic factors alters the pathways and machinery for membrane traffic. We will focus on the syntaxins, a family of proteins that appear to specify correct delivery to the apical or basolateral surfaces. We predict that alterations in pathways and machinery (e.g. expression of various syntaxins) may correlate with the degree of malignancy. Therefore, it may ultimately be possible to examine breast tumor biopsy specimens for the expression of particular syntaxins (or other elements of the polarized trafficking machinery) and use this to predict which tumors will progress. Similarly, it is difficult, yet crucial, to predict how any given tumor will respond to various treatment modalities. Again, examining biopsy specimens for polarized membrane traffic and expression of syntaxins may be very informative as a prognostic or responsive factor.

Finally, and most speculatively, if loss of expression of syntaxins is part of the mechanism of loss of polarity and increased malignancy, then it may be possible to over-express exogenous syntaxins, and thereby partially correct the defect.

Body

The goal of this proposal is to observe the effects of differentiation, de-differentiation, and transformation on polarized membrane traffic in mammary epithelial cells. Epithelial cells contain separate apical and basolateral plasma membranes (PM), with very different protein and lipid compositions (Fig. 1, addendum B). Generating and maintaining PM polarity is essential for the proper growth and function of an epithelium. Loss of polarity is an early and crucial step in the development of malignancy. Polarized expression is especially important for growth and differentiation factors and their receptors. For example, the mistargeting of an apically secreted growth factor to the basolateral PM can result in inappropriate stimulation of its cognate receptor (7, 10). Alternatively, if the delivery of a receptor to the cell surface is blocked and pools of receptor form on internal membranes, interaction with its ligand would again result in an unregulated activation of the receptor (11, 12). During lactation several growth hormones are synthesized and secreted into the milk, including the IGF-family, epidermal growth factor, transforming growth factors (TGF) α and β , tumor necrosis factor, basic fibroblast growth factor and platelet derived growth factor. An autocrine growth response, whereby a tumor cell both expresses and is stimulated by a mitogenic factor, may contribute to the tumorigenicity of neoplastic cells (8, 9).

To establish and maintain their polarity, epithelial cells must send PM proteins to the correct apical or basolateral PM (4, 5, 6). Epithelial cells utilize two major pathways to send proteins to the correct PM. Newly made PM proteins can be sent from the Golgi and trans-Golgi network (TGN) to either the apical or basolateral surface (Fig. 2). Alternatively, proteins can be sent first to one PM, generally the basolateral. The proteins can then be endocytosed and transcytosed across the cell to the apical PM (Fig. 3). Transcytosis to the apical PM is the only mechanism for apical delivery found in all epithelial cells and in some cell types it is the only mechanism for apical delivery. The steady state localization of a protein at a particular PM is the result of the rate of delivery of the protein to that surface and its rate of removal and/or degradation.

Although the steady state localization of several PM proteins has been examined in normal and transformed mammary cells, very little is known about the pathways and mechanisms used for their delivery. In contrast, by far the most work on polarized membrane traffic has been carried out on MDCK cells.

A major discovery in recent years is that almost all intracellular membrane traffic events use a common machinery for membrane fusion (13, 14, 15, 16, 17, 18). Core elements of this machinery include soluble components, NSF and α SNAP. Transport vesicles contain v-SNAREs (vesicular SNAP receptors), such as VAMP-1. The transport vesicles fuse with target membranes, which contain t-SNAREs (target SNAREs). For instance, in neurons, synaptic vesicles containing VAMP-1 fuse with the plasma membrane, containing t-SNAREs. The t-SNAREs consist of two subunits, syntaxins and SNAP-25. (SNAP-25 is unrelated to α SNAP.) A key event in fusion of vesicles is the binding of the v-SNARE to the t-SNARE via their cytoplasmic domains. Both v-SNAREs and t-SNAREs (syntaxins) consist of gene families. It was originally observed in yeast that each step in membrane traffic (e.g. ER to Golgi, Golgi to vacuole, or Golgi to PM) utilized an exclusive pair of v- and t-SNAREs. This led to the hypothesis that the correct pairing of v- and t-SNAREs conferred **specificity** upon vesicle fusion, so that a vesicle could not fuse with the wrong target.

Polarized epithelial cells are an excellent system in which to examine the possible role of SNAREs in conferring specificity, as they contain several classes of vesicles traveling from either the TGN or endosomes to the apical or basolateral PMs. K. Simon's group investigated this by reconstituting traffic in permeabilized MDCK cells (19). Surprisingly, they found that transport from the TGN to the apical PM of at least one protein, influenza virus hemagglutinin (HA), did not require NSF (20, 21). Although these results indicate that the TGN to apical PM pathway of HA uses a non-NSF/SNARE mechanism, molecules can also reach the apical PM by transcytosis. We therefore investigated whether transcytosis of pIgR to the apical PM would also use a non-NSF/SNARE pathway (22). We replicated Simon's permeabilized MDCK cell system and used it to reconstitute transcytosis. We found that transcytosis of

dIgA to the apical PM uses a NSF/SNARE dependent mechanism. Thus, delivery to the apical PM can be either NSF/SNARE dependent or /independent.

The finding that delivery to the apical PM (transcytosis) and the basolateral PM both use NSF/SNAREs leads to the question of whether specificity in apical/basolateral targeting depends on using different SNAREs. Five isoforms of the t-SNARE, syntaxin, occur at the PM of mammalian cells (23). Two of these, syntaxins 1a and 1b, are neuron specific, whereas syntaxins 2, 3, and 4 are abundant in epithelial organs, e.g. liver, kidney, and intestine. In collaboration with Mark Bennett (who discovered syntaxins in R. Scheller's lab and now has his own lab at UC Berkeley), we investigated the location of all of these syntaxins in MDCK cells. Dr. Bennett has used GST fusions with clones of rat syntaxins 1-4 to produce affinity-purified, isoform specific antibodies against each syntaxin. We used these antibodies on western blots of MDCK cells and detected syntaxins 2, 3, and 4.

To investigate the localization of these syntaxins in MDCK cells, Steve Chapin in our lab separately transfected syntaxins 2, 3 or 4 into MDCK cells and isolated cell lines stably expressing individual syntaxins (together with pIgR). We examined the location of each isoform by confocal immunofluorescent microscopy. Syntaxin 2 was primarily on the apical PM, with some staining of the basolateral PM. Syntaxin 3 was on the apical PM and on vesicles in the apical region of the cytoplasm. This agreed completely with the faint staining of the endogenous syntaxin 3. Syntaxin 4 was entirely on the basolateral PM. We conclude that each syntaxin has a unique localization. The localization of syntaxins 2 and 3 at the apical PM is consistent with our finding that at least some membrane traffic to the apical PM uses SNAREs. Most importantly, syntaxins 3 and 4 have a completely non-overlapping distribution and must serve different traffic pathways.

We found that overexpression of syntaxin 3 inhibits TGN to apical delivery. This result suggests that TGN to apical transport of some proteins use an NSF/SNARE dependent mechanism. The other syntaxins had no effect on apical delivery. In contrast to the apical PM effects of overexpression of syntaxin 3, overexpression of syntaxin 4 had an effect on basolateral traffic, e.g. it inhibited recycling of dIgA back to the basolateral surface. (We have not yet analyzed the effects of syntaxin 2 overexpression, but given its location at both the apical and basolateral surfaces, it may be involved in transcytosis between these surfaces.) We do not know why overexpression of syntaxins 3 and 4 had inhibitory effects, but it should be noted that overexpression of syntaxin 1 in insulinoma cells similarly blocks regulated secretion (24), suggesting that the inhibition of membrane traffic by syntaxin overexpression may be a general phenomena. A likely explanation for these results is that the high level of the overexpressed syntaxin drives formation of the syntaxin complex with a v-SNARE, and thereby slows the disassembly of this complex needed for fusion to proceed. It is highly unlikely that the observed effects on membrane traffic are due to nonspecific artifacts of overexpression. The effects of each syntaxin are highly specific to either the apical or basolateral PM. Syntaxin 3 overexpression had no effect on the basolateral PM, while syntaxin 4 had no effect on the apical. The syntaxins are the first family of molecules that are part of the membrane fusion machinery, whose isoforms are differentially localized to the apical or basolateral PMs of polarized cells and whose overexpression has differential effects on polarized membrane traffic. They are therefore the leading candidates for containing at least part of the information needed for vesicular targeting.

When proteins that are sorted to the apical or basolateral PMs of epithelial cells are expressed in non-polarized fibroblasts, these proteins are still sorted in the TGN into cognate apical or basolateral vesicles (25). Apparently, as these cells lack distinct apical and basolateral PMs, the vesicles all fuse with the one common PM. Kai Simons has therefore suggested that the major difference between polarized epithelial cells and non-polarized cells is the presence or absence of the machinery for vesicles to fuse with the correct PM. Our results clearly indicate that syntaxins are part of the machinery needed for this correct targeting. We hypothesize that the repertoire of expressed syntaxins will be diminished in cells that are de-differentiated or transformed.

The mammary gland cycles through a well-known series of growth, differentiation, lactation, and involution steps. As an *in vitro* model, we will use a clonal population selected from the cell line IM-2, derived from spontaneously immortalized, nontumorigenic mouse mammary cells. IM-2 represents a

heterogeneous cell population consisting of both epithelial (31E) and fibroblastic (30F) cells. When cultured in the presence of the lactogenic hormones, IM-2 cells are induced to secrete large amounts of β -casein. When the epithelial cells, 31E, were grown on a permeable support they can be induced to differentiate by the addition of prolactin and glucocorticoid (26). 31E cells form a well polarized monolayer, as shown by EM studies and the establishment of a transepithelial electrical resistance (TER) when grown on permeable supports. Lactate and laminin are released from the basal surface, whereas β -casein is secreted from the apical cell surface (27). 31E cells were subcloned further to generate a more stable homogeneous cell line designated, 31EG4 (28). Reichmann's group isolated virtually identical subclones, IM-Ep-1 and EpH4 (29, 30).

Subcloning of 31EG4 and much of their further characterization described below was performed by Karen Singer Zettl [now Karen Singer], as a graduate student in Prof. Gary Firestone's laboratory at Univ. of California, Berkeley. Dr. Singer is now a postdoctoral fellow in my laboratory, and has been invaluable in preparing this grant proposal, as well as setting up the 31EG4 system. Dr. Singer is now pursuing research that is complementary to this grant proposal, but is non-overlapping, as it considers the effects of TGF α and c-Myc on polarized membrane traffic.

Glucocorticoids, TGF- β , c-Fos and c-Jun are important regulators of both normal mammary development as well as tumorigenesis, and their effects on IM-2 derived cell lines have been examined. Glucocorticoids were initially found to be necessary for the expression of caseins and whey acidic protein in mammary gland explants (reviewed by (31)). Using 31EG4 cells, Zettl et al. (28) defined a new role for glucocorticoids. Cell monolayers grown on permeable supports in the presence of dexamethasone, a synthetic glucocorticoid, resulted in a 64-fold increase in TER and a two fold increase in the expression of the tight junction protein ZO-1. Dexamethasone, in the presence of prolactin, increased the functional polarity of the cell surface (32). This was the first demonstration of an induction of membrane protein polarity of an epithelial cell. Similar results have since been described for Con8 cells, a rat mammary tumor cell line. Growth of Con8 cells was strongly inhibited by dexamethasone (33). When Con8 cells were grown on permeable supports, dexamethasone caused an increase in the TER and the appearance of a more regular monolayer (34). The exogenous addition of TGF- α to the basolateral, but not the apical membrane domain on Con8 cells grown on permeable supports was able to over-ride the growth inhibition of dexamethasone (10). It appeared that the effect of glucocorticoids on this tumorigenic cell line was to induce differentiation. This represents the second example of glucocorticoids regulating the differentiation and function polarity of a membrane bound protein. Examining the changes that take place in the cellular machinery involved in protein trafficking in response to glucocorticoids will help to evaluate the degree of de-differentiation a given tumor has undergone and to define the requirements of the epithelial cell for polarity.

TGF- β and glucocorticoids have antagonistic effects on 31EG4 cells, dependent on the length of time the cells were previously exposed to glucocorticoids (35). When added to mouse mammary gland epithelial cells, NMuMG, TGF- β induced the transdifferentiation of epithelial cells to mesenchymal cells (36). R. Derynck's lab found that NMuMG cells decreased their expression of epithelial markers E-cadherin, ZO-1, and desmoplakins I and II, and increased the expression of the mesenchymal marker fibronectin. (Dr. Derynck will serve as a consultant to this proposal; see included letter). Over-expression of TGF- β in mammary gland during pregnancy inhibited development of lobuloalveolar structures and suppressed production of milk proteins (37). Therefore the effects of TGF- β on protein trafficking and syntaxin expression should be representative of the physiological changes during mammary involution.

The AP-1 nuclear transcription factors fall into two distinct groups: c-Jun and c-Fos. c-Fos members are only able to form heterodimers with c-Jun members, whereas c-Jun members can form both homodimers with other members or heterodimers with other Fos members (38). Over-expression of c-Fos will drive the formation of heterodimers. Over-expression of c-Jun will drive the formation of homodimers. Studies on at least one promoter element, the p1fG composite element of the protein, proliferin, indicate that it is stimulated by the glucocorticoid receptor when Jun/Jun homodimers are bound, but repressed when Fos/Jun heterodimers are bound. There are many examples of genes that are activated by Fos/Jun and repressed by the glucocorticoid receptor. In this way, growth factors that work

by stimulating the expression of Fos or Jun can affect the expression of many different gene products. The interaction between the glucocorticoid receptor and AP-1 is again indicative of how important glucocorticoids are, and how the ablation of hormones at the end of lactation signals the large change in gene expression involved in involution.

Overexpression of Fos or Fos and Jun in epithelial clones from IM-2 cells inhibited the ability of the lactogenic hormones to stimulate β -casein (29, 30). In turn, glucocorticoids were found to decrease endogenous AP-1 expression levels. Prolonged expression of Fos caused an irreversible loss of cell polarity and TER (30). The apical marker dipeptidyl peptidase IV (DPP IV) became randomly expressed over the entire cell surface, while the normally basolateral cell adhesion protein, E-cadherin, was first localized apically as well as basolaterally and then later was absent. Cell morphology became fibroblastoid with the eventual expression of the mesenchymal markers, vimentin and fibronectin. To regulate the expression of c-Fos and c-Jun in these studies, they were expressed as fusion proteins with the estrogen receptor (designated c-FosER and c-JunER). Binding of estrogen to the fusion protein caused activation of the c-Fos or c-Jun (29, 39).

The expression of c-JunER in epithelial cells derived from IM-2 cells resulted in a less severe loss of epithelial cell polarity (39). Unlike the case with c-FosER, cell polarity was recovered after removal of estrogen. Activation of c-JunER caused the redistribution of the apical marker DPP IV along with normally apically restricted microvilli to form all over the cell surface, loss of TER, and the down regulation of E-cadherin and ZO-1. Removal of estrogen resulted in the return of monolayer TER, which is a good indication of a well polarized monolayer. Therefore, the effects initiated by the overexpression of c-Jun maybe easier to decipher. The cell is induced to transdifferentiate by Fos/Jun. Instead the transactivating events initiated by Jun/Jun homodimers predominate, and the cell undergoes a more limited loss of cell polarity. This may represent the first step toward tumorigenesis.

In summary, alterations in mammary epithelial cell polarity in response to glucocorticoids (increased polarity), TGF- β (decreased polarity, but dependent on prior exposure to glucocorticoids), c-jun (reversible loss in cell polarity), and c-fos (irreversible loss of polarity) reflect a spectrum of differentiation and tumorigenic potential.

We have started by examining membrane traffic in control 31EG4 cells, which form a well polarized monolayer on permeable Transwell supports. We used the same basic strategy and assays we developed for analysis of membrane traffic in MDCK cells. We have published details of all these methods, using both transfected pIgR and endogenous markers (E-cadherin for the basolateral PM, DPP IV for the apical PM) (6, 40, 41). For instance, delivery of pIgR or E-cadherin from the TGN to the basolateral surface is measured by metabolically labeling pIgR and E-cadherin with a 10 min pulse with ^{35}S -Cys. Cells are then chased for various periods of up to 60 min. The arrival of pIgR or E-cadherin at the basolateral surface is then determined by labeling proteins at the basolateral PM with a membrane impermeant biotinylation reagent (sulfo-NHS-biotin). (A duplicate set of filters is used to measure mis-delivery to the apical PM). The pIgR or E-cadherin are then immunoprecipitated, and the immunoprecipitates reprecipitated with streptavidin-agarose. These are then analyzed by SDS-PAGE and fluorography. This procedure measures the rate and accuracy of delivery of a protein to the basolateral PM. To measure delivery to the apical PM we can use DPP IV or transfected pIgR with a mutant basolateral signal, which is sent directly to the apical surface. A theoretical problem is that when cells lose their tight junctions, the sulfo-NHS-biotin can leak between cells and non-specifically label both surfaces. However, in experiments thus far, we have found that if the labeling with biotin is performed for short periods (e.g. 5 min at 4°C), this is a very minor problem and does not interfere with our analysis.

To measure transcytosis, we allow cells expressing the pIgR to endocytose radioiodinated IgA (^{125}I -IgA) from the basolateral surface for 5 min. The cells are then washed and the subsequent release of ^{125}I -IgA into the apical medium (transcytosis) and basolateral medium (recycling) is measured over a 120 min period. For transcytosis, we will transfect the cells with the wild-type pIgR, and assay transcytosis of dIgA.

We are using the spectrum of treatments described above to perturb polarity to various degrees and examine the effects on traffic. For glucocorticoids, we will use dexamethasone (1 nM), which is expected to increase polarity. Addition of TGF β (10 ng/ml) causes a partial loss of polarity. The effects of TGF β are maximal by 72 hr, although we can also examine shorter treatments to observe partial effects. For Fos and Jun we can stably transfect cells with c-FosER or c-JunER constructs. These are expressed using a retroviral vector system. We obtained the necessary constructs and have prior experience with using these vectors and packaging cell lines to infect MDCK cells. Treatment of the cells with β -estradiol (E2) causes highly specific activation of these chimeric oncogenes. A possible drawback is that the E2 alone may affect cell polarity. As an alternative, we can use the tetracycline controlled transactivator system developed by Bujard and colleagues. We have successfully used this system in MDCK cells to obtain very tightly regulated and highly inducible expression of a variety of genes. The original version of this system involves sequentially transfecting the cells with two plasmids, encoding either the tetracycline sensitive transactivator or the gene of interest (e.g. c-Fos or c-Jun) under the control of a promoter that is responsive to this transactivator. Cells are grown in the presence of tetracycline, which normally represses expression of the gene of interest. When tetracycline is removed, the gene of interest is turned on. Several improved versions of this system have been described, although we have so far only used the original version in MDCK cells.

In all cases we used confocal immunofluorescence microscopy of several marker proteins (E-cadherin, ZO-1, etc.), electron microscopy (conventional and immuno) and transepithelial electrical resistance to verify that the changes in polarity are consistent with previously reported results. We will then use the array of assays described above to determine the effects on membrane traffic.

FIGURES.

Fig. 1. Epithelial cell polarity




Fig 2. Polarized Sorting from TGN




Fig. 3. Transcytosis and Polarized Sorting in Endosomes





Fig. 4. Pathway of the plgR..



Conclusions:

We have begun a systematic examination of the pathways of membrane traffic in normal and transformed mammary epithelial cells. This work is laying the groundwork for fulfillment of the complete research program of this grant, to understand how membrane traffic is altered in mammary cancer and how it may be possible to restore it to normalcy.

References

1. J. R. Harris, M. E. Lippman, U. Veronesi, W. Willett, *N. Engl. J. Med.* **327**, 473-480 (1992).
2. J. R. Harris, M. E. Lippman, U. Veronesi, W. Willett, *N. Engl. J. Med.* **327**, 390-398 (1992).
3. J. R. Harris, M. E. Lippman, U. Veronesi, W. Willett, *N. Engl. J. Med.* **327**, 319-328 (1992).
4. K. E. Mostov, M. H. Cardone, *BioEssays* **17**, 129-138 (1995).
5. K. E. Mostov, et al., *Cold Spring Harb. Symp. Quant. Biol.* **60**, 775-781 (1995).
6. K. Mostov, G. Apodaca, B. Aroeti, C. Okamoto, *J. Cell Biol.* **116**, 577-583 (1992).
7. D. B. Alexander, L. Goya, M. K. Webster, T. Haraguchi, G. L. Firestone, *Cancer Res.* **53**, 1808-1815 (1993).
8. S. Baghdiguian, B. Verrier, C. Gerard, J. Fantini, *Cancer Lett.* **62**, 23-33 (1992).
9. M. Remacle-Bonnet, F. Garrouste, F. el Atiq, J. Marvaldi, G. Pommier, *J. Clin. Invest.* **96**, 192-200 (1995).
10. P. Buse, P. L. Woo, D. B. Alexander, A. Reza, G. L. Firestone, *J. Biol. Chem.* **270**, 28223-28227 (1995).
11. M. Cross, M. T. Dexter, *Cell* **64**, 271-280 (1991).
12. F. Nicolas, M. C. Tiveron, J. Davoust, H. Reggio, *J. Cell Sci.* **107**, 2679-2689 (1994).
13. R. H. Scheller, *Neuron* **14**, 893-897 (1995).
14. M. K. Bennett, *Curr. Biol.* **7**, 581-586 (1995).
15. J. E. Rothman, G. Warren, *Curr. Biol.* **4**, 220-233 (1994).
16. T. Sudhof, *Nature* **375**, 645-653 (1995).
17. J. Pevsner, S.-C. Hsu, R. H. Scheller, *Proc. Natl. Acad. Sci. U.S.A.* **91**, 1445-1449 (1994).
18. J. Pevsner, R. H. Scheller, *Curr. Opin. Cell Biol.* **6**, 555-560 (1994).
19. E. Ikonen, M. Tagaya, O. Ullrich, C. Montecucco, K. Simons, *Cell* **81**, 571-580 (1995).
20. I. Mellman, *Cell* **82**, 869-872 (1995).
21. K. L. Wilson, *Cell* **81**, 475-477 (1995).
22. G. Apodaca, M. H. Cardone, S. W. Whiteheart, B. R. DasGupta, K. E. Mostov, *EMBO* **15**, 1471-1481 (1996).
23. M. K. Bennett, et al., *Cell* **74**, 863-873 (1993).
24. S. Nagamatsu, et al., *J. Biol. Chem.* **271**, 1160-1165 (1996).
25. T. Yoshimori, P. Keller, M. G. Roth, K. Simons, *J. Cell Biol.* **133**, 247-256 (1996).
26. E. Reichmann, R. Ball, B. Groner, R. R. Friis, *J. Cell Biol.* **108**, 1127-1138 (1989).
27. R. Strange, et al., *Cell Growth Differ.* **2**, 549-559 (1991).
28. K. S. Zettl, et al., *Proc. Natl. Acad. Sci. USA* **89**, 9069-9073 (1992).
29. E. Reichmann, et al., *Cell* **71**, 1103-1116 (1992).
30. B. Jehn, et al., *Mol. Cell Biol.* **12**, 3890-3902 (1992).
31. J. M. Rosen, et al., *Ann N Y Acad. Sci.* **478**, 63-76 (1986).
32. M. D. Sjaastad, K. S. Zettl, G. Parry, G. L. Firestone, T. E. Machen, *J. Cell Biol.* **122**, 589-600 (1993).
33. L. Goya, et al., *Cancer Res.* **53**, 1816-1822 (1993).
34. P. Buse, et al., *J. Biol. Chem.* **270**, 6505-6514 (1995).
35. P. L. Woo, H. H. Cha, K. L. Singer, G. L. Firestone, *J. Biol. Chem.* **271**, 404-412 (1996).
36. P. J. Miettinen, R. Ebner, A. R. Lopez, R. Derynck, *J. Cell Biol.* **127**, 2021-2036 (1994).
37. C. Jhappan, et al., *EMBO J.* **12**, 1835-1845 (1993).
38. J. N. Miner, K. R. Yamamoto, *Genes Dev.* **6**, 2491-2501 (1992).
39. I. Fialka, et al., *J. Cell Biol.* **132**, 1115-1132 (1996).
40. T. Crepaldi, et al., *J. Cell Biol.* **125**, 313-320 (1994).
41. J. E. Casanova, G. Apodaca, K. E. Mostov, *Cell* **66**, 65-75 (1991).

APPENDICES: ABBREVIATIONS

dIgA	dimeric IgA
DPP IV	dipeptidyl peptidase IV
MDCK	Madin-Darby canine kidney cells
NSF	N-ethyl maleimide sensitive factor
pIgR	polymeric immunoglobulin receptor
PM	plasma membrane
SC	secretory component
α -SNAP	soluble NSF attachment protein
SNAP-25	synaptosomal associated protein of 25kD
TGF α	transforming growth factor α
TGF β	transforming growth factor β
TER	transepithelial electrical resistance
TGN	trans-Golgi network
t-SNARE	target SNAP receptor
v-SNARE	vesicle SNAP receptor
WT	wild-type